FDA approves BridgeBio’s Attruby for ATTR-CM treatment
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...
BridgeBio: Next Chapter Begins After Attruby Approval
2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
The Pharma Letter46m
BridgeBio’s Attruby wins FDA approval
The US Food and Drug Administration (FDA) on Friday approved Attruby (acoramidis), an orally-administered near-complete (≥90% ...
pharmaphorum3h
BridgeBio poised to challenge Pfizer after Attruby approval
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although BridgeBio ...
devdiscourse6h
BridgeBio's Breakthrough in Rare Heart Condition Treatment
The U.S. FDA has approved Attruby, a new drug by BridgeBio, for treating a rare heart condition, redefining a market led by ...
BioSpace6h
FDA Action Alert: Applied Therapeutics Awaits Verdict on Rare Disease Therapy
With two decisions originally scheduled for this week already announced, including BridgeBio's approval in ATTR-CM, the ...
devdiscourse11h
FDA Highlights and Health Concerns: From Heart Drugs to Mpox Updates
This summary of health news features the FDA's approval of BridgeBio's heart drug, studies on cancer indicators in healthy ...
pharmaphorum1h
Makary confirmed as Trump's FDA pick, with Weldon for CDC
Rumours that Donald Trump had chosen Martin Makary as FDA Commissioner have been confirmed, while the President-elect has ...
Indiatimes11h
India News
During an address to the Bihari diaspora in the US, political strategist Prashant Kishor characterized Bihar as a "failed state," drawing parallels to Sudan and emphasizing the state's dire need ...